Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Profund Advisors LLC

Profund Advisors LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 5.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 201,303 shares of the biopharmaceutical company’s stock after selling 10,871 shares during the quarter. Gilead Sciences accounts for about 0.9% of Profund Advisors LLC’s holdings, making the stock its 18th biggest position. Profund Advisors LLC’s holdings in Gilead Sciences were worth $12,418,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wealthfront Advisers LLC grew its holdings in Gilead Sciences by 64.1% in the second quarter. Wealthfront Advisers LLC now owns 141,138 shares of the biopharmaceutical company’s stock valued at $8,724,000 after purchasing an additional 55,110 shares during the last quarter. Avantax Planning Partners Inc. acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $229,000. Clear Creek Financial Management LLC purchased a new stake in Gilead Sciences in the 2nd quarter valued at approximately $202,000. Charter Oak Capital Management LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at $81,000. Finally, Brookstone Capital Management increased its position in Gilead Sciences by 5.7% during the third quarter. Brookstone Capital Management now owns 169,160 shares of the biopharmaceutical company’s stock worth $11,061,000 after buying an additional 9,145 shares in the last quarter. 78.72% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CAO Diane E. Wilfong sold 6,416 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $83.50, for a total value of $535,736.00. Following the completion of the transaction, the chief accounting officer now owns 28,333 shares in the company, valued at approximately $2,365,805.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Gilead Sciences news, CAO Diane E. Wilfong sold 16,255 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $79.25, for a total value of $1,288,208.75. Following the transaction, the chief accounting officer now owns 28,333 shares of the company’s stock, valued at $2,245,390.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Diane E. Wilfong sold 6,416 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total value of $535,736.00. Following the transaction, the chief accounting officer now directly owns 28,333 shares of the company’s stock, valued at $2,365,805.50. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on GILD shares. Piper Sandler upped their price objective on Gilead Sciences from $104.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, January 19th. Royal Bank of Canada lowered shares of Gilead Sciences from an “outperform” rating to a “sector perform” rating and set a $87.00 target price on the stock. in a report on Tuesday, January 3rd. DZ Bank downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Friday, December 9th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Friday, October 28th. Finally, Wells Fargo & Company boosted their price target on Gilead Sciences from $75.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, January 3rd. Nine equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.40.

Gilead Sciences Stock Down 0.0 %

Shares of Gilead Sciences stock traded down $0.03 on Wednesday, hitting $83.99. 1,015,032 shares of the company’s stock traded hands, compared to its average volume of 6,159,364. The company has a quick ratio of 1.16, a current ratio of 1.30 and a debt-to-equity ratio of 1.14. The firm’s 50-day moving average is $85.92 and its 200 day moving average is $73.22. The stock has a market cap of $105.34 billion, a P/E ratio of 31.71, a PEG ratio of 0.80 and a beta of 0.45. Gilead Sciences, Inc. has a 52-week low of $57.17 and a 52-week high of $89.74.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.44 by $0.46. The firm had revenue of $7.04 billion for the quarter, compared to the consensus estimate of $6.12 billion. Gilead Sciences had a net margin of 12.29% and a return on equity of 38.51%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.08 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 29th. Investors of record on Thursday, December 15th were issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend was Wednesday, December 14th. Gilead Sciences’s dividend payout ratio is currently 110.19%.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.